The company will report its earnings for FY 2017 on 03/22/2018. Generally, the company reports earnings worse than estimates. In recent months, the 3 analysts from Thomson Reuters consensus have revised their EPS estimates downward.
Annual earnings per share is expected at -0.11 EUR for 2017 (- 90.2% from 2016). A summary of annual publications and estimates is available below.
Poxel is a biopharmaceutical company specializing in developing innovative treatments for metabolic diseases, including non-alcoholic steatohepatitis (NASH) and rare diseases.
TWYMEEG® (Imeglimine), Poxel's lead product and the first in its class of medicines, which targets mitochondrial dysfunction, has been marketed in Japan for the treatment of type 2 diabetes.
For the treatment of NASH, the PXL065 met its primary endpoint in a streamlined Phase II trial, and PXL770 has completed a Phase IIa proof-of-concept study by reaching its objectives. In adrenoleukodystrophy (ALD), a rare inherited metabolic disease, the company intends to initiate Phase IIa proof-of-concept studies with the PXL065 and the PXL770 in patients with adrenomyeloneuropathy (AMN).
POXEL 
